Interim consolidated financial information and review report YIACO Medical Company KSC (Closed) and Subsidiaries Kuwait

30 June 2007 (Unaudited)

# YIACO Medical Company KSC (Closed) and Subsidiaries Kuwait

# Contents

	Page
Review report	1
Consolidated income statement	2
Consolidated balance sheet	3
Consolidated cash flow statement	4
Consolidated statement of changes in equity	5
Notes to the interim financial information	6 to 11

# Grant Thornton 震 Anwar Al-Qatami & Co

Auditors & Consultants

Souq Al Kabeer Building - Block A - 9th Floor Tel: (965) 244 3900-9

Fax: (965) 243 8451

P.O.Box 2986, Safat 13030 - Kuwait

E-mail: gt@gtkuwait.com



P.O. Box 74 Safat 13001 Safat, Kuwait Souk As Safat, 3rd Floor Abdullah Mubarak Street

■ Tel: 245 2880 Fax: 245 6419

# Review report

To the board of directors of YIACO Medical Company KSC (Closed)

### Report on review of interim consolidated financial information

We have reviewed the accompanying consolidated balance sheet of YIACO Medical Company KSC (Closed) (the parent company) and Subsidiaries (together "the group") as at 30 June 2007 and the related consolidated income statement for the three-month and six-month periods then ended, and the statement of changes in shareholders' equity and cash flows statement for the six month period then ended. The directors of the parent company are responsible for the preparation and presentation of this interim consolidated financial information in accordance with International Accounting Standard 34, "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim consolidated financial information based on our review.

### Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We did not review the interim financial information of Al-Kamal Import and Marketing Company WLL and Universal Industrial Medical Company E.S.C. That financial information has been reviewed by other independent auditors whose review report thereon has been provided to us and our report, in so far as it relates to the amounts included for these subsidiaries is based solely on the report of other auditors. The total assets and profits of these subsidiaries included in these interim consolidated financial information are KD3,627,583 and KD113,746 respectively.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim consolidated financial information is not prepared, in all material respects, in accordance with IAS 34, "Interim Financial Reporting".

### Report on other legal and regulatory requirements

Furthermore, based on our review, the interim consolidated financial information is in agreement with the books of the parent company. We further report that, to the best of our knowledge and belief, no violations of the Commercial Companies Law of 1960, as amended, nor of the articles of association of the parent company, as amended, have occurred during the six month period ended 30 June 2007 that might have had a material effect on the business of the parent company or on its financial position.

Abdullatif M. Al-Aiban (CPA)

(Licence No. 94-A)

of Grant Thornton - Anwar Al-Qatami & Co.

Waleed A. Al-Osaimi (Licence No. 68-A) of Ernst & Young

Kuwait

7 August 2007

# **Consolidated income statement**

	Notes	(Unau Three mon			dited) hs ended
		30 June 2007 KD	30 June 2006 KD	30 June 2007 KD	30 June 2006 KD
Sales Cost of sales		13,077,979 (11,055,116)	12,264,982 (9,585,780)	24,601,837 (19,239,745)	23,725,715 (18,375,284)
Gross profit		2,022,863	2,679,202	5,362,092	5,350,431
Other operating income Selling and distribution costs Administration expenses		144,421 (594,404) (1,930,527)	146,095 (469,472) (1,928,760)	326,516 (1,000,501) (3,855,476)	287,605 (933,149) (3,541,958)
(Loss)/profit from operations Share in results of associate Unrealised (loss)/gain on investments at		(357,647) -	427,065 (19,412)	832,631	1,162,929 (119,010)
fair value through statement of income Dividend income Finance costs Management remuneration		(9,300) 22,000 (119,163) 42,887	849,200 22,000 (227,902) (42,567)	14,700 57,650 (264,661) (47,875)	267,642 44,000 (461,675) (94,365)
(Loss)/profit for the period before					
Income tax		(421,223) (27,958)	1,008,384 (16,648)	592,445 (47,061)	799,521 (18,042)
(Loss)/profit for the period from continuing operations Profit for the period from discontinued operation	4	(449,181)	991,736	545,384	781,479
(Loss)/profit for the period before	<del>"</del>	<u> </u>	230,916	-	411,441
contribution to Kuwait Foundation for the Advancement of Sciences (KFAS) Contribution to KFAS		(449,181) 4,077	1,222,652 (11,106)	545,384 (4,853)	1,192,920 (11,106)
(Loss)/profit for the period		(445,104)	1,211,546	540,531	1,181,814
Attributable to: Shareholders of the parent company Minority interest		(448,952) 3,848	1,209,654 1,892	534,356 6,175	1,179,748 2,066
		(445,104)	1,211,546	540,531	1,181,814
Basic and diluted (loss)/earnings per share					
- From continuing operations - From discontinued operations	3	(2.99) Fils -	6.52 Fils 1.54 Fils	3.56 Fils -	5.12 Fils 2.74 Fils
		(2.99) Fils	8.06 Fils	3.56 Fils	7.86 Fils

The notes set out on pages 6 to 11 form an integral part of this interim financial information.

# Consolidated balance sheet

	Notes	(Unaudited) 30 June 2007 KD	(Audited) 31 Dec. 2006 KD	(Unaudited) 30 June 2006 KD
Assets				N.D
Non-current assets				
Property and equipment		8,130,871	8,546,906	10,151,437
Intangible assets Key money		399,501	533,001	-
Deferred costs		84,250	104,794	80,863
Goodwill	5	1,048,082	1,094,271	1,332,220
Investment in associates	5	135,292 12,500	10 500	40.500
Investments at fair value through statement of income	6	2,462,800	12,500 2,448,100	12,500 5,415,695
Available for sale investments	Ŭ	5,138,379	5,138,379	5,415,695
	***************************************	17,411,675	17,877,951	22,131,094
_				
Current assets				
Inventories		9,238,907	8,362,285	10,431,514
Accounts receivable and prepayments  Cash and bank balances		12,713,081	16,870,587	13,967,053
Oddit and bank balances	7	4,020,292	1,731,421	1,907,092
700		25,972,280	26,964,293	26,305,659
Total assets		43,383,955	44,842,244	48,436,753
Equity and liabilities Equity Share capital Legal reserve Voluntary reserve General reserve Retained earnings Foreign currency translation reserve  Equity attributable to the shareholders of the parent company Minority interest		15,000,000 1,721,982 120,622 637,472 2,571,951 143,584 20,195,611 98,285	15,000,000 1,721,982 120,622 637,472 3,537,595 149,654 21,167,325 92,413	15,000,000 1,476,890 120,622 637,472 2,529,909 140,130 19,905,023 93,662
Total equity	******			
		20,293,896	21,259,738	19,998,685
Non-current liabilities Long term loans Provision for staff indemnity Provisions	8	750,000 935,709	900,000 926,379	1,050,000 1,186,656
Murabaha payable	9	800,000 1,380,616	800,000 1,807,801	- 220 700
				2,330,730
- Man		3,866,325	4,434,180	4,567,386
Current liabilities				
Current portion of term loans	8	1,306,704	1,300,000	2,557,000
Accounts payable and accruals	_	15,724,287	14,052,248	14,927,988
Current portion of murabaha payable	9	1,854,852	3,307,232	4,599,717
Bank overdrafts	7	337,891	488,846	1,785,977
		19,223,734	19,148,326	23,870,682
Total equity and liabilities		43,383,955	44,842,244	48,436,753

Dr. Hamed A. Hamadah Chairman & Managing Director

The notes set out on pages 6 to 11 form an integral part of this interim financial information.

# Consolidated cash flow statement

Profit for the period		Notes	(Unaudited) Six months ended 30 June 2007 KD	(Unaudited) Six months ended 30 June 2006 KD
Depreciation and amortisation   \$89,570   \$81,1092   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$11,9101   \$12,948   \$11,234   \$12,248	Profit for the period			
Unrealised gain on investments at fair value through statement of income   14,700   128,48   15,234   10,236	Depreciation and amortisation		698,570	
Finance cost	Unrealised gain on investments at fair value through statement of income Provision for staff indemnity		102,968	(284,542) 116,234
Property plant and equipment written off Income tax	Finance cost		264,661	463,685
Working capital changes:         1,569,824         2,256,501           Inventories         (876,622)         (16,978)           Accounts receivable and prepayments         2,665,136         (3,569,714)           Accounts payable and accruals         1,651,830         2,351,042           Cash from operations         5,010,228         1,020,851           Income tax paid         (47,061)         (18,042)           Finance cost paid         (47,061)         (483,863)           Staff indemnity paid         (93,633)         (83,434)           Net cash from operating activities         4,604,868         530,780           INVESTING ACTIVITIES           Acquisition of subsidiary – net of cash         (139,644)         -           Purchase of property and equipment         (34,042)         (520,193)           Proceeds from disposal of property and equipment         (34,042)         (520,193)           Proceeds from disposal of property and equipment         38,404         37,564           Payment for deferred cost         (139,835)         -           Recovery of deferred cost         (138,835)         -           Payment for deferred cost         (50,003)         27,738           Dividend received         57,650         52,000	Property plant and equipment written off		•	10,437
Inventoriaes			***************************************	
Accounts receivable and prepayments         2,665,136         (3,59,714)           Accounts payable and accruals         1,651,890         2,351,042           Cash from operations         5,010,228         1,020,851           Income tax paid         (47,061)         (48,045)           Finance cost paid         (93,638)         (8,344)           Net cash from operating activities         4,604,868         530,780           INVESTING ACTIVITIES           Acquisition of subsidiary – net of cash         (139,644)         -           Purchase of property and equipment         (130,125)         (520,193)           Proceeds from disposal of property and equipment         (133,634)         37,564           Payment for deferred cost         (193,835)         -           Peurchase of investments at fair value through statement of income         (10,25,458)         27,738           Transfer of investment in associates to investment in consolidated subsidiary         57,650         52,000           Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES         (1,25,458)         (1,27,526)         (1,26,568)           Net payment for Murabaha         (1,373,258)         (570,216)         (1,575,216)           Net payment for term loans	Inventories		(876,622)	(16,978)
Income tax paid   (47,061)   (18,042)   Finance cost paid   (264,661)   (463,685)   (264,661)   (463,685)   (83,638)   (83,444)				(3,569,714)
Staff indemnity paid         (93,638)         (8,344)           Net cash from operating activities         4,604,868         530,780           INVESTING ACTIVITIES           Acquisition of subsidiary – net of cash         (139,644)         -           Purchase of property and equipment         (130,125)         (520,193)           Proceeds from disposal of property and equipment         38,404         37,564           Payment for deferred cost         240,024         279,527           Purchase of investments at fair value through statement of income         -         (1,025,458)           Transfer of investment in associates to investment in consolidated subsidiary         -         27,738           Dividend received         57,650         52,000           Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES           Net payment for Murabaha         (1,879,565)         (570,216)           Net payment for term loans         (151,578)         (185,000)           Net cash used in financing activities         (6,373)         -           Exchange differences         (6,373)         -           Increase/(decrease) in cash and cash equivalents         2,439,826         (1,373,258)           Cash and cash equivalents at	Income tax paid		(47,061)	(18,042)
INVESTING ACTIVITIES	Staff indemnity paid			
Acquisition of subsidiary – net of cash       (139,644)       -         Purchase of property and equipment       (130,125)       (520,193)         Proceeds from disposal of property and equipment       38,404       37,564         Payment for deferred cost       (193,835)       -         Recovery of deferred costs       240,024       279,527         Purchase of investments at fair value through statement of income       -       (1,025,458)         Transfer of investment in associates to investment in consolidated subsidiary       -       27,738         Dividend received       57,650       52,000         Net cash used in investing activities       (127,526)       (1,148,822)         FINANCING ACTIVITIES         Net payment for Murabaha       (1,879,565)       (570,216)         Net payment for term loans       (181,578)       (185,000)         Net cash used in financing activities       (2,031,143)       (755,216)         Exchange differences       (6,373)       -         Exchange differences       (6,373)       -         Cash and cash equivalents at the beginning of the period       7       1,242,575       1,494,373         Cash and cash equivalents at the end of the period       7       3,682,401       121,115         Non-cash transacti	Net cash from operating activities		4,604,868	530,780
Purchase of property and equipment         (130,125)         (520,193)           Proceeds from disposal of property and equipment         38,404         37,564           Payment for deferred costs         (193,835)         -           Recovery of deferred costs         240,024         279,527           Purchase of investments at fair value through statement of income         -         (1,025,458)           Transfer of investment in associates to investment in consolidated subsidiary         57,650         52,000           Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES           Net payment for Murabaha         (1,879,565)         (570,216)           Net payment for term loans         (151,578)         (185,000)           Net cash used in financing activities         (2,031,143)         (755,216)           Exchange differences         (6,373)         -           Increase/(decrease) in cash and cash equivalents         2,439,826         (1,373,258)           Cash and cash equivalents at the beginning of the period         7         1,242,575         1,494,373           Cash and cash equivalents at the end of the period         7         3,682,401         121,115           Non-cash transaction:				
Recovery of deferred costs         240,024         279,527           Purchase of investments at fair value through statement of income         -         (1,025,458)           Transfer of investment in associates to investment in consolidated subsidiary         -         27,738           Dividend received         57,650         52,000           Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES           Net payment for Murabaha         (1,879,565)         (570,216)           Net payment for term loans         (151,578)         (185,000)           Net cash used in financing activities         (2,031,143)         (755,216)           Exchange differences         (6,373)         -           Increase/(decrease) in cash and cash equivalents         2,439,826         (1,373,258)           Cash and cash equivalents at the beginning of the period         7         1,242,575         1,494,373           Cash and cash equivalents at the end of the period         7         3,682,401         121,115           Non-cash transaction:	Purchase of property and equipment Proceeds from disposal of property and equipment		(130,125) 38,404	
Transfer of investment in associates to investment in consolidated subsidiary Dividend received         27,738 52,000           Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES           Net payment for Murabaha Net payment for term loans         (1,879,565) (1570,216) (185,000)         (570,216) (185,000)           Net cash used in financing activities         (2,031,143) (755,216)         (755,216)           Exchange differences         (6,373) -         -           Increase/(decrease) in cash and cash equivalents         2,439,826 (1,373,258)         (1,373,258)           Cash and cash equivalents at the beginning of the period         7 1,242,575 1,494,373         1,494,373           Cash and cash equivalents at the end of the period         7 3,682,401 121,115         121,115           Non-cash transaction:	Recovery of deferred costs			
Net cash used in investing activities         (127,526)         (1,148,822)           FINANCING ACTIVITIES           Net payment for Murabaha Net payment for term loans         (1,879,565)         (570,216)           Net cash used in financing activities         (2,031,143)         (755,216)           Exchange differences         (6,373)         -           Increase/(decrease) in cash and cash equivalents         2,439,826         (1,373,258)           Cash and cash equivalents at the beginning of the period         7         1,242,575         1,494,373           Cash and cash equivalents at the end of the period         7         3,682,401         121,115           Non-cash transaction:	Transfer of investment in associates to investment in consolidated subsidiary		- 57 650	27,738
FINANCING ACTIVITIES Net payment for Murabaha Net payment for term loans  Net cash used in financing activities  Exchange differences  Exchange differences  (6,373)  Increase/(decrease) in cash and cash equivalents  Cash and cash equivalents at the beginning of the period  7  1,242,575  1,494,373  Cash and cash equivalents at the end of the period  7  3,682,401  121,115  Non-cash transaction:	Net cash used in investing activities			
Net payment for Murabaha Net payment for term loans         (1,879,565) (185,000)         (570,216)           Net cash used in financing activities         (2,031,143)         (755,216)           Exchange differences         (6,373)         -           Increase/(decrease) in cash and cash equivalents         2,439,826         (1,373,258)           Cash and cash equivalents at the beginning of the period         7         1,242,575         1,494,373           Cash and cash equivalents at the end of the period         7         3,682,401         121,115           Non-cash transaction:				
Exchange differences (6,373) - Increase/(decrease) in cash and cash equivalents 2,439,826 (1,373,258)  Cash and cash equivalents at the beginning of the period 7 1,242,575 1,494,373  Cash and cash equivalents at the end of the period 7 3,682,401 121,115  Non-cash transaction:	Net payment for Murabaha			
Increase/(decrease) in cash and cash equivalents  Cash and cash equivalents at the beginning of the period  7 1,242,575 1,494,373  Cash and cash equivalents at the end of the period  7 3,682,401 121,115  Non-cash transaction:	Net cash used in financing activities		(2,031,143)	(755,216)
Cash and cash equivalents at the beginning of the period 7 1,242,575 1,494,373  Cash and cash equivalents at the end of the period 7 3,682,401 121,115  Non-cash transaction:	Exchange differences		(6,373)	<u>-</u>
Cash and cash equivalents at the end of the period 7 3,682,401 121,115  Non-cash transaction:	Increase/(decrease) in cash and cash equivalents		2,439,826	(1,373,258)
Non-cash transaction:	Cash and cash equivalents at the beginning of the period	7	1,242,575	1,494,373
	Cash and cash equivalents at the end of the period	7	3,682,401	121,115
		11	1,500,000	-

The notes set out on pages 6 to 11 form an integral part of this interim financial information.

# YIACO Medical Company KSC (Closed) and Subsidiaries Kuwait

# Consolidated statement of changes in equity

		Attribu	Attributable to shareholders of the parent company	holders of th	e parent com	pany		Minority interest	Total equity
	Share capital KD	Legal reserve KD	Voluntary reserve KD	General reserve KD	Retained earnings KD	Foreign currency translation reserve	<b>Total</b> KD	8	. Q
Balance at 1 January 2007 Foreign currency translation reserve	15,000,000	1,721,982	120,622	637,472	3,537,595	149,654 (6,070)	21,167,325 (6,070)	92,413 (303)	21,259,738 (6,373)
Total income for the period recognised directly in equity Profit for the period	1 1	t t	1 (	1 1	534,356	(6,070)	(6,070) 534,356	(303) 6,175	(6,373) 540,531
Total recognised income for the period Dividend paid (Note 11)	1 1	i t	1 1	1 \$	534,356 (1,500,000)	(6,070)	528,286 (1,500,000)	5,872	534,158 (1,500,000)
Balance at 30 June 2007	15,000,000	1,721,982	120,622	637,472	2,571,951	143,584	20,195,611	98,285	20,293,896
Balance at 1 January 2006	15,000,000	1,476,890	120,622	637,472	1,350,161	140,130	18,725,275	91,596	18,816,871
Profit and total income for the period	•	1	1	t	1,179,748	î	1,179,748	2,066	1,181,814
Balance at 30 June 2006	15,000,000	1,476,890	120,622	637,472	2,529,909	140,130	19,905,023	93,662	19,998,685

The notes set out on pages 6 to 11 form an integral part of this interim financial information.

# Notes to the interim consolidated financial information 30 June 2007

### 1 Incorporation and activities

YIACO Medical Company KSC (Closed) (parent company) was incorporated on 15 January 1969 in accordance with the Commercial Companies Law in Kuwait to carry out general trading only. Its principal activities are the import and sale of medical, chemical and dental products and equipment. The parent company also operates a number of pharmacies in Kuwait and a medical clinic.

Previously, the parent company was a subsidiary of The Securities House, a Kuwaiti closed shareholding company. During the period, The Securities House KSCC sold major portion of its ownership interest in the parent company. Consequently, the parent company is no longer a subsidiary of The Securities House KSCC.

The address of the parent company's registered office is PO Box 435, Safat 13005, State of Kuwait.

The group comprises of the parent company and its following subsidiaries:

- a) Al Kamal Import and Marketing Company WLL (KIMC) Egypt, a 95% subsidiary, is engaged in import, marketing and manufacturing medical raw material and medical and chemical equipment.
- b) Universal Industrial Medical Company, Egypt, a 100% subsidiary, is engaged in manufacturing laboratory chemicals, medical supplies, pharmaceuticals and children's food and packing of the company's products in Egypt.
- c) Gulf International Company for Tourism WLL, Kuwait, a 100% subsidiary, engaged in providing private travel services.
- d) Al Raya Health Care Company WLL, Kuwait, a 100% subsidiary, engaged in providing medical services.

The group mainly operates in Kuwait and Egypt.

This interim consolidated financial information of the group for the six-month period ended 30 June 2007 were authorised for issue by the board of directors on 7 August 2007.

### 2 Basis of presentation

The interim consolidated financial information of the group has been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. The accounting policies used in the preparation of the interim consolidated financial information are consistent with those used in the preparation of the annual consolidated financial statements of the group for the year ended 31 December 2006.

The interim consolidated financials statements have been presented in Kuwaiti Dinars which is the functional currency of the parent company.

The interim consolidated financial information does not contain all information and disclosures required for full consolidated financial statements prepared in accordance with International Financial Reporting Standards, and should be read in conjunction with the group's annual consolidated financial statements as at 31 December 2006. In addition, results for the six months ended 30 June 2007 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2007.

### 3 Basic and diluted (loss)/earnings per share

Basic and diluted (loss)/earnings per share are calculated by dividing the (loss)/profit for the period attributable to the shareholders of the parent company by the weighted average number of shares outstanding during the period.

		Three months ended (Unaudited)		ths ended udited)
	30 June 2007	30 June 2006	30 June 2007	30 June 2006
(Loss)/profit for the period attributable to shareholders of the parent company from continuing operations (KD)	(448,952)	978,738	534,356	768,307
Profit for the period attributable to shareholders of the parent company from discontinued operations (KD)	-	230,916	-	411,441
	(448,952)	1,209,654	534,356	1,179,748
Weighted average number of shares outstanding during the period	150,000,000	150,000,000	150,000,000	150,000,000
Basic and diluted (loss)/earnings per share - from continuing operations - from discontinued operations	(2.99) Fils -	6.52 Fils 1.54 Fils	3.56 Fils -	5.12 Fils 2.74 Fils

### 4 Discontinued operations

On 23 September 2006, the group entered into a sale agreement, effective 30 June 2006, to sell its wholly owned subsidiary, Hygiene Products Industries Company – KSC (Closed), to its ultimate parent company, The Securities House – KSC (Closed). The sale amount was equal to the carrying value of the subsidiary in the books of the group. Hence no gain or loss resulted on disposal.

The profit for the period from discontinued operations is analysed below:

	Three months ended (Unaudited)		Six months ended (Unaudited)	
	30 June 2007 KD	30 June 2006 KD	30 June 2007 KD	30 June 2006 KD
Sales Cost of sales	-	1,239,746 (788,506)	-	2,599,412 (1,667,374)
Gross profit Other operating income Selling and distribution costs Administration expenses	-	451,240 (1,217) (161,012) (117,259)	-	932,038 1,786 (313,554) (231,719)
Profit from operations Unrealised gain on investments at fair value through statement of income Dividend income Finance costs	- - -	171,752 56,300 4,000 (1,136)	- - -	388,551 16,900 8,000 (2,010)
Profit for the period	w	230,916	•	411,441

### 4 Discontinued operations (continued)

The net assets of Hygiene Products Industries Company – KSC (Closed) is at 30 June 2006 as follows:

Assets	30 June 2006 (Unaudited) KD
Property, plant and equipment Inventories Investments at fair value through statement of income Accounts receivable and prepayments Cash and bank balances	1,217,888 746,793 442,095 1,188,640 1,015,513
Total assets	4,610,929
Less: Liabilities Employees' end of service benefits Term loans Accounts payable and accruals	(281,481) (7,000) (380,849)
Total liabilities	(669,330)
Total net assets	3,941,599

### 5 Acquisition

During the period, the group acquired 100% ownership of Al Raya Health Care Company – WLL. Details of the net assets acquired on 31 May 2007 (date of acquisition) are as follows:

KD
25,143
10,356 7,630
17,986
43,129
(8,282) (20,139)
(28,421)
14,708
150,000 (14,708)
135,292
(150,000) 10,356
(139,644)

### 6 Investments at fair value through statement of income

This represents the investments made in the equity securities fund which is managed by the ultimate parent company and local unquoted shares.

### 7 Cash and cash equivalents

Cash and cash equivalents included in the consolidated statement of cash flows represent the following consolidated balance sheet amounts:

	30 June	31 Dec.	30 June
	2007	2006	2006
	(Unaudited)	(Audited)	(Unaudited)
	KD	KD	KD
Bank balances and cash	4,020,292	1,731,421	1,907,092
Bank overdrafts	(337,891)	(488,846)	(1,785,977)
	3,682,401	1,242,575	121,115

Bank overdrafts carry interest rate of 8.75 % (31 December 2006: 8.75% and 30 June 2006: 8.5%) per annum and are unsecured.

### 8 Term loans

Term loans represent loans payable to local banks. The loans carry interest at an average rate of 7.75% to 8.25.% (31 December 2006: 7.5% to 8.25% and 30 June 2006: 7.5% to 8%) per annum on the utilized portion and are unsecured. The loans are payable on different dates ending on 31 December 2010. Amounts payable within the next twelve months are shown as current liabilities.

### 9 Murabaha payable

Murabaha payable represents the value of commodities purchased on a deferred settlement basis and carries effective profit payable rates ranging from 8% to 9.75% (31 December 2006: 8% to 10% and 30 June 2006: 7% to 9.75%). The murabaha is payable on different dates ending 31 May 2015 and are secured over property and equipment and inventories with net book value of KD 6,916,216. Amount payable within the next twelve months are shown as current liabilities.

### 10 Contingent liabilities

At 30 June 2007, the group had contingent liabilities in respect of outstanding letters of guarantees amounting to KD7,346,279 (31 December 2006: KD7,175,473 and 30 June 2006: KD7,159,475). The group had capital commitments in respect of assets under construction of KD Nil (31 December 2006: KD Nil and 30 June 2006: KD875,656). Also the group had commitments to invest amounting to KD315,000 (31 December 2006: KD315,000 and 30 June 2006: KD315,000).

### 11 Dividend paid

At the annual general meeting of the shareholders held on 4 April 2007, cash dividend of 10 Fils (31 December 2006: KD Nil and 30 June 2006: KD Nil) per share of the paid up capital amounting to KD1,500,000 (31 December 2006: KD Nil and 30 June 2006: KD Nil) were approved. Dividend amounting to KD1,500,000 due to The Securities House – KSCC (previous ultimate parent company) was offset against amounts receivable from the same.

### 12 Segmental Information

The group's primary basis of segment reporting by business segments, which consist of medical and related activities and investments.

An analysis of gross income, profit, total assets and total liabilities in respect of each of these segments is as follows:

Six months ended 30 June 2007 (Unaudited)	Medical and related activities KD	Investments KD	Total KD
Segment revenue	24,601,837	72,350	24,674,187
Segment profit from continuing operations	473,034	72,350	545,384
Unallocated expenses	***************************************		(4,853)
Profit for the period			540,531
Three months ended 30 June 2007 (Unaudited) Segment revenue	13,077,979	12,700	13,090,679
Segment (loss)/profit from continuing operations	(461,881)	12,700	(449,181)
Unallocated income			4,077
Loss for the period			(445,104)
At 30 June 2007 (Unaudited) Total assets	35,770,276	7,613,679	43,383,955
Total liabilities	(23,090,059)	-	(23,090,059)
Six months ended 30 June 2006 (Unaudited) Segment revenue	23,725,715	311,642	24,037,357
Segment profit from continuing operations Segment profit from discontinued operations	469,837 -	311,642	781,479 411,441
Unallocated expenses			(11,106)
Profit for the period	W-20.	- WAL	1,181,814
Three months ended 30 June 2006 (Unaudited) Segment revenue	12,264,982	871,200	13,136,182
Segment profit from continuing operations Segment profit from discontinued operations	120,536	871,200	991,736 230,916
Unallocated expenses		The state of the s	(11,106)
Profit for the period			1,211,546
At 30 June 2006 (Unaudited) Total assets	37,870,179	10,566,574	48,436,753
Total liabilities	(28,438,068)	_	(28,438,068)

### 12 Segmental Information (continued)

The group reports its secondary segmental information according to geographical location of its customers and assets as follows:

At 20 June 2007 (smoothing)	Kuwait KD	Egypt KD	Total KD
At 30 June 2007 (unaudited) Segment revenue	22,588,799	2,085,388	24,674,187
Total assets	39,756,372	3,627,583	43,383,955
Total liabilities	(21,518,227)	(1,571,832)	(23,090,059)
At 30 June 2006 (unaudited) Segment revenue	22,882,372	1,154,985	24,037,357
Total assets	44,394,273	4,042,480	48,436,753
Total liabilities	(26,373,997)	(2,064,071)	(28,438,068)

### 13 Comparative amounts

The comparative amounts have been reclassified to conform to the current period's presentation. Such amounts do not affect previously reported profit or equity.